Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Robertson, Lindsay ^a   Kesteven, Patrick ^a   Mccaslin, James E ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DALTEPARIN; EDOXABAN; ENOXAPARIN; FLUINDIONE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN; XIMELAGATRAN; ANTITHROMBIN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ALL CAUSE MORTALITY; ANTICOAGULANT THERAPY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; DABIGATRAN; FACTOR XA INHIBITORS; HUMANS; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIVAROXABAN; THIAZOLES; VENOUS THROMBOSIS;

EID: 84946945500     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010956.pub2     Document Type: Review

References (111)

1. Agnelli G. Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine 2013;159(8):JC2.
2. Agnelli G, Buller H, Masiukiewicz UP. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis 2013;11(Suppl):18.
3. Agnelli G, Buller HR, Cohen A, Curto D, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine 2013;369:799-808.
4. NCT00633893 . Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&rank=5 (accessed 1 March 2014).
5. Barrett YC, Wang J, Knabb R, Mohan P. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis 2011;105:181-9.
6. Buller HR. A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - The Botticelli Investigators. XXIst Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva 2007.
7. NCT00252005 . Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study, 2007. clinicaltrials.gov/ct/show/NCT00252005?order=1 (accessed 1 March 2014).
8. On behalf of the Botticelli Investigators, The Writing Committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis 2008;6:1313-8.
9. Buller H, Darius H. EINSTEIN DVT: Oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. www.escardio.org/congresses/esc-2010/congress-reports/Pages/708-4-EINSTEIN-DVT.aspx#.UvNXl03itMs 2010.
10. Buller HR, Agnelli G. Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood 2006; Vol. 108, issue 11 Part 1:172-3.
11. Buller HR, Lensing AWA, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008;112(6):2242-7.
12. NCT00395772 . Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The Einstein-DVT dose-finding study, 2006. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&rank=2 (accessed 1 March 2014).
13. Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis 2013;110(4):732-41.
14. Buller HR. Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood (ASH Annual Meeting Abstracts) 2010;116:187.
15. Prins M, Bamber L, Cano S, Wang M, Lensing AWA, Bauersachs R. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120:1163.
16. Prins MH, Lensing AW, Bauersachs R, Van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal 2013;11(1):21.
17. Prins MHE. Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis 2013;11(Suppl):257.
18. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine 2010;363(26):2499-510.
19. Van Bellen B, Prins M, Bamber L, Wang M, Lensing AWA. Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program. Current Medical Research and Opinion 2014;30(5):829-37.
20. Wang Y, Wang C. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis 2013;11(Suppl):694.
21. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine 2012;366:1287-97.
22. NCT00439777 . Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&rank=1 (accessed 1 March 2014).
23. Prins M, Bamber L, Cano S, Wang M, Lensing AWA, Bauersachs R. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood (ASH Annual Meeting Abstracts) 2012;120(21):1163.
24. The Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine 2012;366:1287-97.
25. Raskob G, Buller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis 2013;11(7):1287-94.
26. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine 2013;369(15):1406-15.
27. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116:180-7.
28. Piazza G, Mani V, Grosso M, Mercuri M, Lanz H, Schussler S, et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation 2014;130:A12074.
29. NCT00291330 . Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I), 2007. clinicaltrials.gov/ct/show/NCT00291330?order=1 (accessed 1 March 2014).
30. Schulman S, Eriksson H, Goldhaber S, Kakkar AK, Kearon C, Kvamme AM, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis 2011; Vol. 9, issue Suppl 2:22.
31. Schulman S, Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, Mismetti P, et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis 2013;11(Suppl 2):225-6.
32. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine 2009;361(24):2342-52.
33. Schulman S. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood 2011;118(21):95-6.
34. Schulman S, Baanstra D, Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, et al. Benefit of extended maintenance therapy for venous thromboembolism with dabigatran etexilate is maintained over 1 year of post-treatment follow-up. Blood (ASH Annual Meeting Abstracts) 2012;120:21.
35. Schulman S, Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, Mismetti P, et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis 2013;11:225-6.
36. Schulman S, Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, Schellong SM, et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood (ASH Annual Meeting Abstracts) 2013;122:2375.
37. Schulman S, Eriksson H, Goldhaver SZ, Kakkar A, Kearon C, Mismetti P, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation 2014;130:A18594.
38. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72.
39. Eriksson H, Lundstrom T, Wahlander K, Clason SB, Schulman S. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thrombosis and Haemostasis 2005;94(3):522-7.
40. Eriksson H, Wahlander K, Lundstrom T, Billing CS, Schulman S. Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood. 2002; Vol. 100:81a.
41. Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, for the THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis 2003;1:41-7.
42. Francis CW, Ginsberg JS, Berkowitz SD, Bounameaux H, Davidson BL, Eriksson H, et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood 2003; Vol. 102, issue 11:Abstract 7.
43. Huisman MV, The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis 2003; Vol. 1, issue Suppl 1 July:Abstract OC003.
44. Schulman S, Lundstrom T, Walander K, Billing CS, Eriksson H. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study 1828. Thrombosis and Haemostasis 2005;94(4):820-4.
45. Wimperis J, Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE Treatment Study. British Journal of Haematology 2004;125(Suppl 1):66.
46. Ageno W, Mantovani LG, Haas S, Kreutz R, Haupt V, Schneider J, et al. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thrombosis Journal 2014;12(1):16.
47. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. New England Journal of Medicine 2013;368(8):699-708.
48. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson MR, et al. Two doses of apixaban for the extended treatment of venous thromboembolism. Blood (ASH Annual Meeting Abstracts) 2012;120:LBA-1.
49. Liu X, Thompson J, Phatak H, Mardekian J, Porcari AR, Johnson MR. Apixaban reduces hospitalization in patients with venous thromboembolism: an analysis of the AMPLIFY-EXT trial. Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013:21.
50. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra A, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine 2013;368:709-18.
51. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine 2013;368(8):709-18.
52. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA 2005;293(6):681-9.
53. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, THRIVE III I. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine 2003;349(18):1713-21.
54. ChiCTR-TRC-14005223 . Efficacy and safety of rivaroxaban or warfarin on venous thromboembolic disease: a randomized controlled trial. www.chictr.org/en/proj/show.aspx?proj=10248 (accessed 1 February 2015).
55. NCT01516840 . Venous thromboembolism (VTE) treatment study in Japanese deep vein thrombosis (DVT) patients. clinicaltrials.gov/show/NCT01516840 (accessed 1 March 2014).
56. NCT01662908 . A randomized, open-label, parallel-group, multi-center study for the evaluation of efficacy and safety of edoxaban monotherapy versus low molecular weight (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis (eTRIS). clinicaltrials.gov/show/NCT01662908 (accessed 1 March 2014).
57. NCT01684423 . Oral rivaroxaban in children with venous thrombosis (EINSTEIN Junior). clinicaltrials.gov/show/NCT01684423 (accessed 1 March 2014).
58. NCT01780987 . A study to evaluate safety and efficacy of apixaban in Japanese acute deep vein thrombosis (DVT) and pulmonary embolism (PE) patients. clinicaltrials.gov/show/NCT01780987 (accessed 1 March 2014).
59. NCT01895777 . Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). clinicaltrials.gov/show/NCT01895777 (accessed 1 March 2014).
60. NCT01986192 . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (accessed 1 March 2014).
61. NCT02234843 . EINSTEIN Junior Phase III: oral rivaroxaban in children with venous thrombosis (EINSTEINJr). clinicaltrials.gov/ct2/show/NCT02234843 (accessed 1 February 2015).
62. NCT02309411 . EINSTEIN Junior phase II: oral rivaroxaban in young children with venous thrombosis (EINSTEIN Jr). hclinicaltrials.gov/ct2/show/NCT02309411 (accessed 1 February 2015).
63. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl 2):e44S-88S.
64. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116(2):180-7.
65. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine 2013;369(9):799-808.
66. Antoniazzi S, Berdai D, Conti V, Robinson P, Radice S, Clementi E, et al. Risk of major bleeding with dabigatran versus active controls: a systematic review and meta-analysis. Congres de Physiologie de Pharmacolgoie et de Therapeutique. 22-24 April 2013.
67. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008;28(11):1354-73.
68. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells P, Stevenson MD, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e351S-418S.
69. Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis 2008;6(8):1313-8.
70. Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemporary Clinical Trials 2006;27(5):432-40.
71. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011;342:d3036.
72. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013;347:f5133.
73. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2009;361(12):1139-51.
74. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
75. Eikelboom JW, Weitz JI. Update on antithrombotic therapy: new anticoagulants. Circulation 2010;121(13):1523-32.
76. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine 2010;363(26):2499-510.
77. Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis 2003;1(1):41-7.
78. Eriksson BI, Dahl OE, Rosenecher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis 2007;5(11):2178-85.
79. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics 2009;48(1):1-22.
80. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498.
81. Gomez-Outes A, Terleira-Fernandez AI, Lecumberri R, Suarez-Gea ML, Vargas-Castrillon E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research 2014;134(4):774-82.
82. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
83. Hirschl M, Kundi M. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. Vasa 2014;43(5):353-64.
84. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine 2007;167(9):935-43.
85. Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies and directions for future research. Blood Reviews 2002;16(3):155-65.
86. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. The Lancet 2014;383(9920):880-8.
87. Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 2005;60(6):565-74.
88. Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research 2014;133:1145-51.
89. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S.
90. Koster A, Fischer KG, Harder S, Mertzlufft F. The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT. Biologics 2007;1(2):105-12.
91. Lee CJ, Ansell JE. Direct thrombin inhibitors. British Journal of Clinical Pharmacology 2011;72(4):581-92.
92. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. for the ARG-911 Study Investigators. Clinical investigation and reports. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43.
93. National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of thromboembolic diseases and the role of thrombophilia testing, 2012. guidance.nice.org.uk/CG144 (accessed 11 January 2014).
94. National Institute of Health and Care Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism, 2012. guidance.nice.org.uk/TA261 (accessed 11 January 2014).
95. National Institute for Health Care and Excellence. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE Technology Appraisal Guidance (TA327), 2014. www.nice.org.uk/guidance/ta327 (accessed 22 June 2015).
96. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal 2011;32(22):2781-9.
97. Palladino M, Merli G, Thomson L. Evaluation of the oral direct factor Xa inhibitor - betrixaban. Expert Opinion on Investigational Drugs 2013;22(11):1465-72.
98. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
99. Robertson L, Kesteven P. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010957]
100. Sardar P, Chatterjee S, Mukherjee D. Efficacy and safety or new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomised controlled trials. Drugs 2013;73:1171-82.
101. Schulman S, Kearon C, and the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis 2005;3(4):692-4.
102. Schulman S, Kakkar AK, Schellong SM, Goldhaber SZ, Henry E, Mismetti P. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood 2011;118:Abstract 205.
103. Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism: a national clinical guideline, 2010. www.sign.ac.uk/pdf/sign122.pdf (accessed 11 January 2014).
104. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120(15):2954-62.
105. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
106. Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Hartter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). American Heart Journal 2012;163(6):931-7.
107. van der Huille T, Den Exter PL, Dekkers OM, Klok FA. Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis 2014;12:320-8.
108. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine 1996;101(5):502-7.
109. Weitz JI. A novel approach to thrombin inhibition. Thrombosis Research 2003;109(Suppl 1):S17-22.
110. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. New England Journal of Medicine 2003;349(13):1227-35.
111. Robertson L, Kesteven P. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010956]